China Traditional Chinese Medicine Holdings Co. Limited released an updated roster of its Board of Directors and detailed the latest composition of its four Board committees as of 17 July 2026.

The Board now comprises 12 directors: • Executive Directors (3): Chairman Guo Jinhong, Li Hongjian and Peng Li. • Non-executive Directors (5): Li Xiangrong, Zu Jing, Xu Jinghui, Chen Kun and Huang Hao. • Independent Non-executive Directors (4): Xie Rong, Yu Tze Shan Hailson, Qin Ling and Li Weidong.

Committee leadership and membership are as follows: 1. Audit Committee – chaired by Independent Non-executive Director Xie Rong; members include Yu Tze Shan Hailson, Qin Ling and Li Weidong. 2. Remuneration and Evaluation Committee – chaired by Qin Ling; members are Li Hongjian, Xie Rong, Yu Tze Shan Hailson and Li Weidong. 3. Nomination Committee – chaired by Guo Jinhong; members include Li Hongjian, Xie Rong, Qin Ling and Li Weidong. 4. Strategic Committee – chaired by Guo Jinhong; members comprise Li Hongjian, Peng Li, Li Xiangrong, Zu Jing, Xu Jinghui, Chen Kun, Yu Tze Shan Hailson and Qin Ling.

The disclosure clarifies governance responsibilities, identifying two committee chairs from the executive ranks—Guo Jinhong (Nomination and Strategic Committees)—and two from the independent non-executive cohort—Xie Rong (Audit) and Qin Ling (Remuneration and Evaluation). The structure reflects the company’s adherence to Hong Kong corporate governance practices that emphasize independent oversight across key Board functions.